These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38190833)

  • 21. Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany.
    Cossmann A; Hoffmann M; Stankov MV; Lürken K; Morillas Ramos G; Kempf A; Nehlmeier I; Pöhlmann S; Behrens GMN; Dopfer-Jablonka A
    Lancet Infect Dis; 2024 Mar; 24(3):e145-e146. PubMed ID: 38211602
    [No Abstract]   [Full Text] [Related]  

  • 22. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
    Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
    Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longevity of the humoral and cellular responses after SARS-CoV-2 booster vaccinations in immunocompromised patients.
    Oyaert M; De Scheerder MA; Van Herrewege S; Laureys G; Van Assche S; Cambron M; Naesens L; Hoste L; Claes K; Haerynck F; Kerre T; Van Laecke S; Jacques P; Padalko E
    Eur J Clin Microbiol Infect Dis; 2024 Jan; 43(1):177-185. PubMed ID: 37953413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study.
    Yang LM; Costales C; Ramanathan M; Bulterys PL; Murugesan K; Schroers-Martin J; Alizadeh AA; Boyd SD; Brown JM; Nadeau KC; Nadimpalli SS; Wang AX; Busque S; Pinsky BA; Banaei N
    J Clin Virol; 2022 Aug; 153():105217. PubMed ID: 35714462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humoral and Cellular Immune Response Elicited by Two Doses of mRNA BNT162b2 Vaccine Against SARS-CoV-2 in People Living with HIV.
    Vanetti C; Milazzo L; Ardizzone F; Oreni L; Cappelletti G; Trabattoni D; Biasin M
    AIDS Res Hum Retroviruses; 2023 Sep; 39(9):495-499. PubMed ID: 37031355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex.
    Korosec CS; Farhang-Sardroodi S; Dick DW; Gholami S; Ghaemi MS; Moyles IR; Craig M; Ooi HK; Heffernan JM
    Sci Rep; 2022 Dec; 12(1):21232. PubMed ID: 36481777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
    Schramm R; Costard-Jäckle A; Rivinius R; Fischer B; Müller B; Boeken U; Haneya A; Provaznik Z; Knabbe C; Gummert J
    Clin Res Cardiol; 2021 Aug; 110(8):1142-1149. PubMed ID: 34241676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.
    Tauzin A; Gong SY; Beaudoin-Bussières G; Vézina D; Gasser R; Nault L; Marchitto L; Benlarbi M; Chatterjee D; Nayrac M; Laumaea A; Prévost J; Boutin M; Sannier G; Nicolas A; Bourassa C; Gendron-Lepage G; Medjahed H; Goyette G; Bo Y; Perreault J; Gokool L; Morrisseau C; Arlotto P; Bazin R; Dubé M; De Serres G; Brousseau N; Richard J; Rovito R; Côté M; Tremblay C; Marchetti GC; Duerr R; Martel-Laferrière V; Kaufmann DE; Finzi A
    Cell Host Microbe; 2022 Jan; 30(1):97-109.e5. PubMed ID: 34953513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
    Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z
    Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is the BNT162b2 vaccine still effective against the latest variant: XBB.1.5?
    Erdag E; Sultanoglu N; Ozverel CS
    Niger J Clin Pract; 2023 Oct; 26(10):1519-1524. PubMed ID: 37929529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant.
    Stumpf J; Tonnus W; Paliege A; Rettig R; Steglich A; Gembardt F; Kessel F; Kröger H; Arndt P; Sradnick J; Frank K; Tonn T; Hugo C
    Transplantation; 2021 Nov; 105(11):e267-e269. PubMed ID: 34342963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Waning humoral immune response to the BNT162b2 vaccine in heart transplant recipients over 6 months.
    Peled Y; Ram E; Mandelboim M; Lavee J; Sternik L; Segev A; Wieder-Finesod A; Halperin R; Indenbaum V; Levy I; Patel J; Raanani E; Lustig Y; Rahav G
    Am J Transplant; 2022 Jul; 22(7):1931-1932. PubMed ID: 35150072
    [No Abstract]   [Full Text] [Related]  

  • 34. Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia.
    Fu JYL; Pukhari MH; Bador MK; Sam IC; Chan YF
    Viruses; 2023 Mar; 15(4):. PubMed ID: 37112825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity.
    Salvagno GL; Pighi L; Henry BM; Valentini M; Tonin B; Bragantini D; Gianfilippi G; De Nitto S; Plebani M; Lippi G
    Clin Chem Lab Med; 2023 Jun; 61(7):1343-1348. PubMed ID: 36722026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
    Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
    Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees.
    Jäger M; Sonnleitner ST; Dichtl S; Lafon E; Diem G; Walder G; Lass-Flörl C; Wilflingseder D; Posch W
    Front Immunol; 2022; 13():868361. PubMed ID: 35833113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer.
    Ehmsen S; Pedersen RM; Bang LL; Asmussen A; Kragh A; Holm DK; Sydenham TV; Jensen TG; Jeppesen SS; Frederiksen H; Andersen TE; Ditzel HJ
    Cancer Cell; 2023 Apr; 41(4):649-650. PubMed ID: 36804967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Durability of humoral and cell-mediated immune response after SARS-CoV-2 mRNA vaccine administration.
    Mihaylova A; Lesichkova S; Baleva M; Nikolova-Vlahova M; Kundurzhiev T; Kolevski A; Naumova E
    J Med Virol; 2023 Jan; 95(1):e28360. PubMed ID: 36448089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection.
    Gray AN; Martin-Blais R; Tobin NH; Wang Y; Brooker SL; Li F; Gadoth A; Elliott J; Faure-Kumar E; Halbrook M; Hofmann C; Kashani S; Kazan C; Yang OO; Fulcher JA; Grovit-Ferbas K; Rimoin AW; Aldrovandi GM
    PLoS One; 2021; 16(11):e0259703. PubMed ID: 34748607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.